Iterum Therapeutics plc Share Price
Stocks
ITRMF
IE000TTOOBX0
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
20:19:54 08/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -100.00% |
| 04-16 | Eton Pharmaceuticals, Inc. Announces CFO Changes | CI |
| 04-16 | Eton Pharmaceuticals, Inc. Appoints Judith ?Judy? M. Matthews as Executive Vice President, Accounting and Finance | CI |
| Market Cap | 52 46.2 43.12 39.3 74.13 5K 74.82 521.85 202.22 2.56K 195.23 191 8.2K | P/E 2025 * |
-
| P/E 2026 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 52 46.2 43.12 39.3 74.13 5K 74.82 521.85 202.22 2.56K 195.23 191 8.2K | EV / Sales 2025 * |
-
| EV / Sales 2026 * | - |
| Free-Float |
99.22% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Iterum Therapeutics plc
| 1 month | 0 | 0 | |
| Current year | 0 | 0.39 | |
| 1 year | 0 | 0.83 | |
| 3 years | 0 | 3.02 | |
| 5 years | 0 | 11.25 | |
| 10 years | 0 | 195 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tom Loughman
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2016 |
Steven Aronin
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2017 |
Christine Coyne
PRN | Corporate Officer/Principal | 58 | 29/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
David Kelly
CHM | Chairman | 65 | 09/03/2025 |
Michael Dunne
BRD | Director/Board Member | 67 | 21/12/2020 |
Beth Hecht
BRD | Director/Board Member | 62 | 11/03/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/11/25 | Buy | Founder | 6,000 | 0.0125% | ||
| 08/08/25 | Buy | Founder | 15,000 | 0.0356% | ||
| 01/07/25 | Free | Executive/Senior Manager | 200,000 | 0.5783% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | - | - | 52 | ||
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | ||
| -3.11% | -3.53% | +20.19% | +81.44% | 57.39B | ||
| +0.89% | -0.63% | +2.17% | +36.19% | 47.64B | ||
| +0.36% | +0.81% | +342.39% | +742.40% | 44.29B | ||
| -0.96% | -4.50% | +24.96% | +35.38% | 42.5B | ||
| -0.20% | -0.77% | +4.13% | +105.50% | 40.71B | ||
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | ||
| -2.68% | +2.92% | +29.33% | +22.72% | 28.53B | ||
| +0.05% | -1.64% | -8.14% | -11.37% | 24.34B | ||
| Average | -0.20% | -0.53% | +52.63% | +128.54% | 39.05B | |
| Weighted average by Cap. | +0.12% | -0.84% | +56.96% | +138.26% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 800K 711K 663K 605K 1.14M 76.91M 1.15M 8.03M 3.11M 39.32M 3M 2.94M 126M | 10M 8.88M 8.29M 7.56M 14.26M 961M 14.39M 100M 38.89M 491M 37.54M 36.73M 1.58B |
| Net income | -31.4M -27.9M -26.04M -23.73M -44.76M -3.02B -45.18M -315M -122M -1.54B -118M -115M -4.95B | -11.2M -9.95M -9.29M -8.47M -15.97M -1.08B -16.11M -112M -43.55M -550M -42.05M -41.14M -1.77B |
| Net Debt | - | - |
Employees
9
Sell
Buy

Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.000001
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ITRMF Stock
Select your edition
All financial news and data tailored to specific country editions
















